A clinical trial to assess the safety and efficacy of an oral medication called Etrasimod for moderately active ulcerative colitis (UC).

Study completed — 1

About this study

The purpose of this study was to assess the efficacy and safety of Etrasimod in participants with moderately active ulcerative colitis (UC).

Etrasimod is designed to block the movement of some kind of cells in your body (part of your immune system called lymphocytes) to areas of inflammation in the colon.

Etrasimod is an experimental treatment. This means that it is not approved treatment for UC by Regulatory Authorities such as the Therapeutic Goods Administration (TGA) in Australia and the Food and Drug Administration (FDA) in the United States.

Enrolment closed

Contact us to find out more about this research study, quoting reference number 2020.338
Person handling test tubes for research


All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.

This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.

The RMH Clinical Trials Centre
Clinical Trials Centre

The Clinical Trials Centre (CTC) is a dedicated, purpose-built space where we conduct clinical trials.

The CTC is located on Level 2 South. When you arrive, if you are unsure where to go, talk to one of our friendly volunteers or the information desk staff.